CTLA4 and neoplasm: In a model of triple-negative breast cancer (TNBC), OAds demonstrated a synergistic effect when combined with anti-PD-L1 and anti-CTLA-4 immunotherapies, resulting in improved tumor control and extended survival, with 20% of the subjects exhibiting complete suppression of metastasis (12).